Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK
Background The trend towards increased psychotropic drug prescribing in children and adolescents is well recognised in North America and continental Europe. However, it is unclear to what extent these studies are applicable to clinical practice in the United Kingdom (UK). This study was conducted to estimate the prevalence of psychotropic drug prescribing in children and adolescents aged <19 years in general practice in the UK from January 1992 to December 2001. Methods Data were obtained from the General Practice Research Database (GPRD). Annual age- and sex-specific prevalence of psychotropic drug prescribing was calculated. Results A total of 143,079 prescriptions were issued to 34,398 study subjects. Stimulant prescriptions rose significantly from 0.03 per 1,000 (95% confidence interval 0.02–0.04) in 1992 to 2.9 per 1,000 (2.52–3.32) in 2001; a 96-fold increase. Methylphenidate accounted for the majority of stimulant prescriptions; 2.4% (349/14,370) of stimulant prescriptions were prescribed to children aged <6 years. Increased prescribing was also noted for antidepressants (1.6-fold), hypnotics/anxiolytics (1.3-fold), antipsychotics (1.3-fold) and anticonvulsants (1.3-fold), whilst the prevalence of clonidine and lithium prescribing remained fairly stable throughout the study period. The use of antidepressant, hypnotic/anxiolytic and anticonvulsant increased with increasing age. A high proportion of boys received stimulants, whereas antidepressants and hypnotics/anxiolytics were more likely prescribed to girls. Conclusion There is an increased trend of psychotropic drug use in children and adolescents in the UK practice. Since most psychotropic drugs are not licensed for use in children at this time, research is needed to investigate the efficacy and long-term safety in this population.
KeywordsPsychotropic drug Children Adolescent Drug utilization Prevalence
- 18.BNF 48. Joint Formulary Committee. British National Formulary. 48th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004.Google Scholar
- 19.Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford, England: Blackwell Science; 1994.Google Scholar
- 20.NICE. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention Deficit/Hyperactivity Disorder (ADHD) in Childhood. Technology Appraisal Guidan no.13.http://www.nice.org.uk/nicemedia/pdf/TA098guidance.pdf. Accessed 6 Dec 2008.
- 32.European Commission. Better medicines for children: proposed regulatory actions on paediatric medicinal products. Brussels, Belgium. 2002. Available from: http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2002/feb/cd_pediatrics_en.pdf. Accessed 6 Dec 2008.
- 33.European Medicines Agency for the Evaluation of Medicines for Human Use (EMEA). EMEA/PEG Procedure for identifying Paediatric Needs. London, UK. 2005. Available from: http://www.emea.europa.eu/pdfs/human/paediatrics/17519205en.pdf. Accessed 6 Dec 2008.